When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...

FOSTER CITY, Calif., April 14, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation ...

The tablet formulation of Brukinsa is supplied as a 160mg dose, allowing patients the convenience of taking only 2 tablets daily. The Food and Drug Administration (FDA) has approved a new tablet ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

In this interview, the main uses and benefits of NIR spectroscopy in tableting are discussed. Oral-solid dosage (OSD) forms remain a popular choice for both pharmaceutical companies and patients.

An early formulation strategy for tablets that is simple and scalable is recommended to ensure fewer downstream problems. The oral solid dosage formulation market is anticipated to experience growth ...

In the pursuit of optimizing tablet performance, CD Formulation, a leading provider of pharmaceutical analysis services, has unveiled a groundbreaking powder flowability testing method. This ...

The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...

Pharmaceutical testing is a must to ensure that all medications meet the top quality, safety, and performance requirements before they enter the market. CD Formulation’s cGMP-compliant laboratory is ...

This unique 3 day course is designed to integrate the key elements of tablet development with hands-on, practical experience in a small scale, lab scale test facility. Each day will consist of ...

The US Food and Drug Administration (FDA) has granted approval to a tablet formulation of BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib). The company formerly known as BeiGene announced ...